- Home
- CPSS vs IPHA Comparison
CPSS vs IPHA Comparison
Compare CPSS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPSS
- IPHA
- Stock Information
- Founded
- CPSS 1991
- IPHA 1999
- Country
- CPSS United States
- IPHA France
- Employees
- CPSS N/A
- IPHA N/A
- Industry
- CPSS Finance: Consumer Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CPSS Finance
- IPHA Health Care
- Exchange
- CPSS Nasdaq
- IPHA Nasdaq
- Market Cap
- CPSS 164.5M
- IPHA 160.1M
- IPO Year
- CPSS 1992
- IPHA 2019
- Fundamental
- Price
- CPSS $8.47
- IPHA $1.79
- Analyst Decision
- CPSS
- IPHA Strong Buy
- Analyst Count
- CPSS 0
- IPHA 3
- Target Price
- CPSS N/A
- IPHA $5.00
- AVG Volume (30 Days)
- CPSS 29.1K
- IPHA 26.2K
- Earning Date
- CPSS 11-06-2025
- IPHA 09-17-2025
- Dividend Yield
- CPSS N/A
- IPHA N/A
- EPS Growth
- CPSS N/A
- IPHA N/A
- EPS
- CPSS 0.80
- IPHA N/A
- Revenue
- CPSS $192,257,000.00
- IPHA $14,839,695.00
- Revenue This Year
- CPSS $143.76
- IPHA $22.29
- Revenue Next Year
- CPSS $14.32
- IPHA $43.84
- P/E Ratio
- CPSS $10.59
- IPHA N/A
- Revenue Growth
- CPSS 2.04
- IPHA N/A
- 52 Week Low
- CPSS $6.67
- IPHA $1.29
- 52 Week High
- CPSS $12.73
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CPSS 57.42
- IPHA 36.43
- Support Level
- CPSS $7.61
- IPHA $1.95
- Resistance Level
- CPSS $8.57
- IPHA $2.40
- Average True Range (ATR)
- CPSS 0.42
- IPHA 0.11
- MACD
- CPSS 0.07
- IPHA -0.04
- Stochastic Oscillator
- CPSS 86.96
- IPHA 6.15
About CPSS Consumer Portfolio Services Inc.
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.